As such, monoclonal antibodies targeting interleukin-1 beta (IL-1β) in the CANTOS trial resulted in lower cardiovascular events, however total mortality was unaffected due to severe leukopenia and subsequent sepsis [10]. Here, IL1B is linked to Sepsis.